Blood clots and narrowed blood vessels create a difficult engineering problem for modern medicine. Even when a treatment reaches the site of an obstruction, weakened or disrupted circulation can prevent drugs from spreading effectively through the affected region. Poor local flow may also slow the removal of clot fragments and contribute to recurrent vascular disease. A new study describes a miniature endovascular soft robot designed to address this problem directly: instead of merely opening a vessel or delivering medication, the device actively regulates blood flow where treatment is needed.
Reported in Nature Biomedical Engineering, the system combines a magnetically responsive body with a flexible carpet of artificial cilia. The magnetic component allows clinicians to guide the robot through the vascular system and position it near an occluded or narrowed branch. Once it reaches its target, the cilia generate coordinated metachronal waves—traveling patterns of motion similar to those used by biological cilia—to propel surrounding fluid. This separates navigation from flow control, enabling the device to move into place first and then enhance circulation locally without requiring continuous movement of the entire robot.
The distinction is important because conventional endovascular tools generally focus on mechanical intervention. Catheters, guidewires and stents can restore a pathway or deliver a therapeutic agent, but they do not necessarily recreate the flow conditions required for efficient transport. Pharmacological treatments face a similar limitation. A drug introduced upstream may be diluted, diverted through neighboring branches or unable to penetrate stagnant blood beyond an obstruction. By producing fluid motion directly at the diseased site, the soft robot is intended to improve the exchange of blood and therapeutic compounds while reducing dependence on naturally restored circulation.
At the center of the device is its cilia carpet, a flexible structure whose individual elements are actuated by magnetic forces. When the cilia move with carefully timed differences in phase, they create a metachronal wave that travels across the surface. This coordinated motion produces a net pumping effect, even though each individual cilium may oscillate back and forth rather than rotate continuously. The mechanism resembles the transport strategy found in microscopic biological systems, where arrays of cilia move mucus, reproductive fluids or other liquids. In the robot, the same principle is adapted to the confined geometry and demanding flow conditions of blood vessels.
The researchers investigated how the geometry and arrangement of the cilia influence performance. Parameters such as cilium dimensions, spacing, flexibility and the timing of their motion determine how effectively mechanical movement is converted into fluid transport. These factors are especially consequential inside vessels, where the robot must operate in a narrow channel and interact with a viscous, biologically complex liquid. The study examined the flow-regulation mechanism and optimized the structure of the cilia carpet to produce useful circulation without relying on the robot’s physical relocation.
Tests in vessel phantoms were used to evaluate the system under conditions intended to reflect biological environments. Such models allow investigators to control vessel diameter, obstruction geometry, fluid viscosity and flow rate while observing how the robot alters transport around a blockage. The reported experiments showed that the device could regulate flow in different vascular configurations, including situations in which an occlusion obstructed a branch. These tests provided a controlled setting for examining whether the cilia-generated motion could move fluid beyond an obstruction and improve the distribution of agents delivered through the model vessel.
The researchers also assessed the robot’s potential for drug-assisted clot removal. Thrombolytic therapies work by breaking down the protein framework that stabilizes a blood clot, but their effectiveness can be limited when the drug does not reach the clot uniformly or remains in contact with it for too short a time. Local flow enhancement could improve the delivery of the therapeutic agent to the clot surface and promote the exchange of treated and untreated fluid. In the reported experiments, the combination of active flow regulation and drug treatment accelerated clot dissolution, reduced residual obstruction and shortened the time required for recanalization compared with treatment approaches lacking the robot’s pumping action.
The system was further evaluated in large-animal studies, an important step because blood vessels in living organisms introduce factors that are difficult to reproduce in laboratory models. Pulsatile flow, vessel compliance, branching anatomy and interactions with blood cells can all influence the behavior of an endovascular device. According to the study, the robot restored flow in occluded branches and improved the delivery of therapeutic agents in vivo. The results suggest that the approach can operate within a realistic vascular environment while maintaining its two separate functions: magnetic navigation to the target and cilia-based regulation after deployment.
The device’s soft construction may offer advantages in a setting where rigid instruments can damage delicate vessel walls or struggle to adapt to changing anatomy. Its small scale and flexible components are intended to support movement through complex vascular pathways, while magnetic control provides a means of steering from outside the body. At the same time, the approach introduces challenges that will need to be addressed before clinical use. Any endovascular robot must be compatible with imaging and clinical navigation systems, avoid obstructing the vessel, withstand repeated actuation and operate safely in the presence of blood components. The forces generated by the cilia must also be strong enough to improve transport without causing unwanted damage or disturbing unstable clot material.
The study presents the robot as a platform for active, localized vascular therapy rather than as a replacement for existing interventions. Its most significant feature is the ability to modulate flow after arriving at a target site. That capability could be relevant not only to clot dissolution but also to other treatments in which local transport is a limiting factor, including targeted drug delivery and therapies for diseased or poorly perfused vessels. By turning a miniature endovascular device into both a navigation tool and a local fluid regulator, the researchers aim to make vascular treatment more controllable. The findings point toward a future in which robotic systems do more than reach an obstruction: they could reshape the microscopic flow environment around it to help medicines work more efficiently.
Subject of Research: A miniature endovascular soft robot that uses magnetically controlled navigation and cilia-generated metachronal waves to regulate blood flow and improve drug transport in occluded vessels.
Article Title: A miniature endovascular soft robot for active blood flow regulation in occluded vessels
Article References: Fang, K., Wang, Y., Liang, J. et al. “A miniature endovascular soft robot for active blood flow regulation in occluded vessels.” Nature Biomedical Engineering (2026). https://doi.org/10.1038/s41551-026-01771-y
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41551-026-01771-y
Keywords: endovascular soft robot, blood flow regulation, magnetic navigation, artificial cilia, metachronal waves, drug delivery, clot dissolution, vascular occlusion, thrombolysis, biomedical robotics
Tags: active blood flow control in blocked vesselsartificial cilia for fluid propulsionautonomous flow regulation in occluded vesselsbio-inspired fluid propulsion mechanismsbiomedical engineering for vascular diseasesinnovative endovascular therapy technologymagnetically guided endovascular robotMiniature soft robot for blood flow regulationminimally invasive vascular treatment devicesoft robotics in medicinetargeted blood circulation enhancementtreatment of blood clots and vessel narrowing
